Daily cigarette smoking among inpatients for substance use disorders in France, 2010-2020: Commonalities and specificities across substances.

IF 2.2 4区 医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Tobacco Induced Diseases Pub Date : 2024-11-05 eCollection Date: 2024-01-01 DOI:10.18332/tid/194097
Eric Janssen, Mike Vuolo, Guillaume Airagnes
{"title":"Daily cigarette smoking among inpatients for substance use disorders in France, 2010-2020: Commonalities and specificities across substances.","authors":"Eric Janssen, Mike Vuolo, Guillaume Airagnes","doi":"10.18332/tid/194097","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to estimate the prevalence and factors associated with cigarette smoking among patients in treatment for substance use disorders (SUD) in France.</p><p><strong>Methods: </strong>We analyze a nation-wide dataset retrieving information on patients entering treatment for alcohol, opioid and stimulant use disorders between 2010 and 2020. We conduct multilevel Poisson regressions to determine the main factors associated with daily cigarette smoking among all patients who entered treatment for alcohol (n=607122), opioid (n=283381) or stimulant (n=57189) use disorders, and zero-truncated negative-binomial regressions to predict the average number of cigarettes per day.</p><p><strong>Results: </strong>Daily cigarette smoking remains a widespread behavior among patients with SUD (overall prevalence: 72.2%, 95% CI: 72.1-72.3), with lower prevalence of daily cigarette smoking among patients treated for alcohol use disorders (69.9%, 95% CI: 69.8-70.0), and higher for patients treated for opioid (78.8%, 95% CI: 78.6-79.0) or stimulant use disorders (75.8%, 95% CI: 75.4-76.2). There was an overall increase in daily cigarette smoking over time (69.9%, 95% CI: 69.8-70.0 in 2010 vs 76.8%, 95% CI: 76.5-76.9 in 2020); however, the average number of cigarettes per day decreased (17.8 per day, 95% CI: 17.7-17.9 in 2010 vs 16.3 per day, 95% CI: 16.2-16.4 in 2020). The higher the education level, the fewer number of cigarettes per day; conversely, the higher the occupational status, the higher the number of cigarettes.</p><p><strong>Conclusions: </strong>The high prevalence of smoking among patients treated for SUD in France departs from the decreasing trend observed in the general population and remains a source of concern. It is necessary to implement tailored prevention strategies that target specific patient subgroups and increase staff awareness.</p>","PeriodicalId":23202,"journal":{"name":"Tobacco Induced Diseases","volume":"22 ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tobacco Induced Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18332/tid/194097","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: This study aims to estimate the prevalence and factors associated with cigarette smoking among patients in treatment for substance use disorders (SUD) in France.

Methods: We analyze a nation-wide dataset retrieving information on patients entering treatment for alcohol, opioid and stimulant use disorders between 2010 and 2020. We conduct multilevel Poisson regressions to determine the main factors associated with daily cigarette smoking among all patients who entered treatment for alcohol (n=607122), opioid (n=283381) or stimulant (n=57189) use disorders, and zero-truncated negative-binomial regressions to predict the average number of cigarettes per day.

Results: Daily cigarette smoking remains a widespread behavior among patients with SUD (overall prevalence: 72.2%, 95% CI: 72.1-72.3), with lower prevalence of daily cigarette smoking among patients treated for alcohol use disorders (69.9%, 95% CI: 69.8-70.0), and higher for patients treated for opioid (78.8%, 95% CI: 78.6-79.0) or stimulant use disorders (75.8%, 95% CI: 75.4-76.2). There was an overall increase in daily cigarette smoking over time (69.9%, 95% CI: 69.8-70.0 in 2010 vs 76.8%, 95% CI: 76.5-76.9 in 2020); however, the average number of cigarettes per day decreased (17.8 per day, 95% CI: 17.7-17.9 in 2010 vs 16.3 per day, 95% CI: 16.2-16.4 in 2020). The higher the education level, the fewer number of cigarettes per day; conversely, the higher the occupational status, the higher the number of cigarettes.

Conclusions: The high prevalence of smoking among patients treated for SUD in France departs from the decreasing trend observed in the general population and remains a source of concern. It is necessary to implement tailored prevention strategies that target specific patient subgroups and increase staff awareness.

2010-2020 年法国药物使用障碍住院患者每日吸烟情况:不同物质的共性和特殊性。
简介:本研究旨在估算法国接受药物使用障碍(SUD)治疗的患者中吸烟的流行率及其相关因素:本研究旨在估算法国接受药物使用障碍(SUD)治疗的患者吸烟率及其相关因素:我们分析了一个全国范围的数据集,该数据集检索了2010年至2020年间因酒精、阿片类药物和兴奋剂使用障碍而接受治疗的患者信息。我们进行了多层次泊松回归,以确定在所有因酒精(人数=607122)、阿片类药物(人数=283381)或兴奋剂(人数=57189)使用障碍而接受治疗的患者中,与每日吸烟相关的主要因素,并进行了零截断负二叉回归,以预测每日平均吸烟数量:每日吸烟在SDD患者中仍是一种普遍行为(总体吸烟率:72.2%,95% CI:72.1-72.3),在接受酒精使用障碍治疗的患者中,每日吸烟率较低(69.9%,95% CI:69.8-70.0),而在接受阿片类药物(78.8%,95% CI:78.6-79.0)或兴奋剂使用障碍(75.8%,95% CI:75.4-76.2)治疗的患者中,每日吸烟率较高。随着时间的推移,每天吸烟的人数总体上有所增加(2010 年为 69.9%,95% CI:69.8-70.0 vs 2020 年为 76.8%,95% CI:76.5-76.9);但平均每天吸烟的人数有所减少(2010 年为每天 17.8 支,95% CI:17.7-17.9 vs 2020 年为每天 16.3 支,95% CI:16.2-16.4)。教育程度越高,每天吸烟数量越少;相反,职业地位越高,吸烟数量越多:在法国,接受精神分裂症治疗的患者中吸烟率较高,这与在普通人群中观察到的吸烟率下降趋势不同,仍然令人担忧。有必要针对特定患者亚群实施有针对性的预防策略,并提高医务人员的意识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tobacco Induced Diseases
Tobacco Induced Diseases SUBSTANCE ABUSE-PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
CiteScore
5.30
自引率
5.40%
发文量
95
审稿时长
12 weeks
期刊介绍: Tobacco Induced Diseases encompasses all aspects of research related to the prevention and control of tobacco use at a global level. Preventing diseases attributable to tobacco is only one aspect of the journal, whose overall scope is to provide a forum for the publication of research articles that can contribute to reducing the burden of tobacco induced diseases globally. To address this epidemic we believe that there must be an avenue for the publication of research/policy activities on tobacco control initiatives that may be very important at a regional and national level. This approach provides a very important "hands on" service to the tobacco control community at a global scale - as common problems have common solutions. Hence, we see ourselves as "connectors" within this global community. The journal hence encourages the submission of articles from all medical, biological and psychosocial disciplines, ranging from medical and dental clinicians, through health professionals to basic biomedical and clinical scientists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信